Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 13.40 is 68% above its 5-year average of 8.00, near the high end of its 5-year range (0.00–15.31).
As of the fiscal period ended Tuesday, June 30, 2026. 26.20% above its 12-month average of 10.62.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 13.40.
CURRENT RATIO
13.40
CURRENT RATIO AVG TTM
10.62
CURRENT RATIO AVG 3Y
10.34
CURRENT RATIO AVG 5Y
8.00
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+26.20%
CURRENT VS 3Y AVG
+29.62%
CURRENT VS 5Y AVG
+67.55%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.09
median of 456 covered companies
CURRENT VS SECTOR MEDIAN
+333.58%
vs the sector median at left
Coya Therapeutics, Inc.
Market Cap
$113.77M
Current Ratio
13.40
TTM Avg
10.62
3Y Avg
10.34
5Y Avg
8.00
Market Cap
$114.24M
Current Ratio
12.63
TTM Avg
12.83
3Y Avg
15.22
5Y Avg
15.22
Market Cap
$111.17M
Current Ratio
7.28
TTM Avg
6.67
3Y Avg
7.13
5Y Avg
10.02
Market Cap
$117.43M
Current Ratio
3.36
TTM Avg
3.23
3Y Avg
4.24
5Y Avg
6.08
Market Cap
$118.02M
Current Ratio
6.49
TTM Avg
6.44
3Y Avg
8.52
5Y Avg
8.53
Market Cap
$109.49M
Current Ratio
5.68
TTM Avg
5.13
3Y Avg
4.85
5Y Avg
5.20
Market Cap
$118.50M
Current Ratio
2.00
TTM Avg
1.45
3Y Avg
1.62
5Y Avg
1.71
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | $113.77M | 13.40 | 10.62 | 10.34 | 8.00 |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $114.24M | 12.63 | 12.83 | 15.22 | 15.22 |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $111.17M | 7.28 | 6.67 | 7.13 | 10.02 |
| Genelux Corporation (GNLX)vs › | $116.59M | 2.39 | 3.50 | 2.69 | 1.97 |
| Foghorn Therapeutics Inc. (FHTX)vs › | $117.43M | 3.36 | 3.23 | 4.24 | 6.08 |
| Immunic, Inc. (IMUX)vs › | $109.93M | 5.05 | 1.26 | 3.56 | 6.57 |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.02M | 6.49 | 6.44 | 8.52 | 8.53 |
| Apyx Medical Corporation (APYX)vs › | $109.49M | 5.68 | 5.13 | 4.85 | 5.20 |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $118.50M | 2.00 | 1.45 | 1.62 | 1.71 |
| BGM Group Ltd. (BGM)vs › | $118.63M | 1.25 | 2.31 | 3.27 | 2.89 |
Current Ratio
13.40
Quick Ratio
13.40
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 13.40 |
| 2026-03-31 | 15.02 |
| 2025-12-31 | 8.50 |
| 2025-09-30 | 8.73 |
| 2025-06-30 | 7.43 |
| 2025-03-31 | 8.84 |
| 2024-12-31 | 11.59 |
| 2024-09-30 | 15.31 |
| 2024-06-30 | 10.43 |
| 2024-03-31 | 8.64 |
| 2023-12-31 | 8.15 |
| 2023-09-30 | 6.54 |
| 2023-06-30 | 11.78 |
| 2023-03-31 | 13.69 |
| 2022-12-31 | 1.88 |
| 2022-09-30 | 3.38 |
| 2022-06-30 | 6.63 |
| 2022-03-31 | 3.99 |
| 2021-12-31 | 3.99 |
| 2021-09-30 | 0.00 |
| 2021-06-30 | 0.00 |
| 2021-03-31 | 0.00 |
